Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Bulletin Du Cancer|March 20, 2019
[Evolution of the regulatory framework in clinical research]Marie Vanseymortier, Julien Thery, Nicolas PenelJournal of Pharmaceutical Sciences|April 5, 2014
PARP Inhibitors as P-glyoprotein SubstratesDenise Lawlor, Patricia Martin, Steven Busschots, et al.Annals of Surgical Oncology|November 28, 2021
Functional Cerebral MRI Evaluation of Integration of Breast Reconstruction into the Body SchemaClaudia Régis, Marie-Cécile Le Deley, Emilie Bogart, et al.European Journal of Cancer (Oxford, England : 1990)|June 15, 2018
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcomaThomas Brodowicz, Olivier Mir, Jennifer Wallet, et al.Molecular Oncology|February 19, 2013
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutationBritta Stordal, Kirsten Timms, Angela Farrelly, et al.Gynecologic Oncology|May 30, 2020
Severe perioperative morbidity after robot-assisted versus conventional laparoscopy in gynecologic oncology: Results of the randomized ROBOGYN-1004 trialFabrice Narducci, Emilie Bogart, Thomas Hebert, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 22, 2026
Characteristics and outcome of intra-abdominal desmoid-type fibromatosisNicolas Penel, Maud Toulmonde, Jennifer Wallet, et al.International Journal of Cancer|March 8, 2023
Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis valueNicolas Penel, Sylvie Bonvalot, Marie-Cécile Le Deley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type FibromatosisNicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, et al.Pageof 1